227 related articles for article (PubMed ID: 28489605)
41. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
42. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
Döbbeling U
G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
[TBL] [Abstract][Full Text] [Related]
43. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities.
Batista DA; Vonderheid EC; Hawkins A; Morsberger L; Long P; Murphy KM; Griffin CA
Genes Chromosomes Cancer; 2006 Apr; 45(4):383-91. PubMed ID: 16382449
[TBL] [Abstract][Full Text] [Related]
44. CRTC1 rearrangements in the absence of t(11;19) in primary cutaneous mucoepidermoid carcinoma.
Lennerz JK; Perry A; Dehner LP; Pfeifer JD; Lind AC
Br J Dermatol; 2009 Oct; 161(4):925-9. PubMed ID: 19438452
[TBL] [Abstract][Full Text] [Related]
45. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.
Wong HK; Gibson H; Hake T; Geyer S; Frederickson J; Marcucci G; Caligiuri MA; Porcu P; Mishra A
J Invest Dermatol; 2015 Aug; 135(8):2084-2092. PubMed ID: 25806852
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive analysis of PTEN status in Sezary syndrome.
Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
[TBL] [Abstract][Full Text] [Related]
47. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
Elenitoba-Johnson KS; Wilcox R
Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
[TBL] [Abstract][Full Text] [Related]
48. Characterization of the novel Sezary lymphoma cell line BKP1.
Boudjarane J; Essaydi A; Farnault L; Popovici C; Lafage-Pochitaloff M; Beaufils N; Berda-Haddad Y; Lacroix R; Nicolino-Brunet C; Le Treut T; Zattara H; Gabert J; Kahn-Perlès B; Costello R
Exp Dermatol; 2015 Jan; 24(1):60-2. PubMed ID: 25314094
[TBL] [Abstract][Full Text] [Related]
49. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics.
von Holstein SL; Fehr A; Persson M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
Ophthalmology; 2013 Oct; 120(10):2130-8. PubMed ID: 23725736
[TBL] [Abstract][Full Text] [Related]
50. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
51. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
52. Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas.
Salgado R; Gallardo F; Servitje O; Estrach T; García-Muret MP; Romagosa V; Florensa L; Serrano S; Salido M; Solé F; Pujol RM; Espinet B
Cancer Genet; 2011 Jul; 204(7):405-9. PubMed ID: 21872828
[TBL] [Abstract][Full Text] [Related]
53. Aberrant expression of T-plastin in Sezary cells.
Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
[TBL] [Abstract][Full Text] [Related]
54. Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells.
Chong BF; Dantzer P; Germeroth T; Hafner M; Wilson AJ; Xiao G; Wong HK
J Dermatol Sci; 2010 Oct; 60(1):8-20. PubMed ID: 20801618
[TBL] [Abstract][Full Text] [Related]
55.
Rassek K; Iżykowska K; Żurawek M; Pieniawska M; Nowicka K; Zhao X; Przybylski GK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834942
[TBL] [Abstract][Full Text] [Related]
56. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
Su T; Duran GE; Kwang AC; Ramchurren N; Fling SP; Kim YH; Khodadoust MS
Oncoimmunology; 2022; 11(1):2115197. PubMed ID: 36046812
[TBL] [Abstract][Full Text] [Related]
57. Additional Her 2/neu gene copies in patients with Sézary syndrome.
Utikal J; Poenitz N; Gratchev A; Klemke CD; Nashan D; Tüting T; Goerdt S
Leuk Res; 2006 Jun; 30(6):755-60. PubMed ID: 16303179
[TBL] [Abstract][Full Text] [Related]
58. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Cristofoletti C; Bresin A; Picozza M; Picchio MC; Monzo F; Helmer Citterich M; Passarelli F; Frezzolini A; Scala E; Monopoli A; Cantonetti M; Benucci R; D'Atri S; Caprini E; Russo G; Narducci MG
Leukemia; 2019 May; 33(5):1231-1242. PubMed ID: 30518812
[TBL] [Abstract][Full Text] [Related]
59. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
[TBL] [Abstract][Full Text] [Related]
60. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
So CC; Wong KF; Siu LL; Kwong YL
Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
